Should I Buy HAE? HAE 2026 Analysis

Should You Buy Haemonetics Corp (HAE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

59.340

1 Day change

-8.74%

52 Week Range

87.320

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (pre-earnings): setup is technically near-support/oversold, but the dominant catalyst is Q3 earnings, and current positioning/estimates don’t offer a clean edge for an impatient entry.
Price is hovering just above S1 (~64.84) with bearish-but-improving momentum; this is more consistent with a tactical bounce attempt than a confirmed uptrend.
Options imply a large move is priced in (IV far above realized), so the market is already paying up for the earnings event—reducing the attractiveness of chasing shares immediately.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.
No supportive “smart money” confirmation from flows: hedge funds neutral, insiders neutral, and no recent Congress trading data.

Technical Analysis

Trend/Momentum: MACD histogram -0.6 (below zero) but negatively contracting → downside momentum is easing, not reversed.
RSI: RSI(6) ~29.4 → near-term conditions are oversold/washed-out, which can support a short bounce, but it’s not a standalone buy signal.
Moving averages: Converging MAs → consolidation/transition phase; no clear trend confirmation.
Levels:
- Pivot: 67.705 (price below pivot = still technically weak)
- Support: 64.84 (S1), 63.07 (S2) (current post-market ~65.95 is close to support)
- Resistance: 70.57 (R1), 72.34 (R2) (reclaiming pivot would be the first clearer bullish confirmation).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment/positioning: Put/Call OI ratio 0.41 and put/call volume ratio 0.67 skew bullish (more call interest than puts).
Volatility: 30D IV ~64.83 vs Historical Vol ~26.64 and IV percentile ~87 → the options market is pricing a much bigger-than-normal move, consistent with the earnings catalyst.
Activity caveat: reported today’s option volume is extremely low (5 contracts), so the daily volume ratios are less reliable; still, OI skew remains constructive.
Net read: options show bullish tilt, but also expensive implied move into earnings—less attractive for “buy now” timing.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst (Q3, pre-market 2026-02-05): consensus EPS ~~1.25–1.27 (+~~5% YoY).
- Execution track record: over the past two years, HAE has beaten EPS 100% of the time and revenue 88% of the time.
- Margin/quality improvements in latest reported quarter: gross margin up and EPS up strongly (see financials).
- Street targets have broadly moved higher recently (multiple raises), supporting medium-term sentiment if the print is solid.

Neutral/Negative Catalysts

- Top-line pressure: Q3 consensus revenue ~$332.7M (-4.7% YoY) and latest quarter revenue already -5.27% YoY, keeping the narrative sensitive to sales stabilization.
- Estimate revisions (last 3 months): EPS revisions skew negative (8 down vs 3 up); revenue revisions are mixed (4 up / 4 down)—not a clean upward revision cycle into the print.
- Technical context: price remains below pivot (~67.7) with MACD still negative—trend has not confirmed bullish yet.

Financial Performance

Latest quarter provided: 2026/Q2
Revenue: $327.3M, -5.27% YoY → ongoing top-line decline.
Profitability: Net income +14.34% YoY and EPS $0.81 (+22.73% YoY) → earnings growth driven by improved efficiency/mix.
Margins: Gross margin 56.04% (+8.21% YoY) → strong margin expansion is the key positive trend.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: price targets have generally been raised across the Street into late 2025, even when ratings were held or moderated.
Bullish/pro view:
- Baird Outperform with PT raised to $99.
- Mizuho Outperform with PT raised to $90.
- Barrington Outperform with PT $90.
- BTIG Buy with PT $88.
More cautious/neutral view:
- Citi downgraded to Neutral (but PT raised to $88).
- JPMorgan Neutral with PT raised to $74.
- BofA Neutral with PT raised to $90.
Wall Street balance: pros emphasize improving margin trajectory and plasma/hospital execution reset; cons center on revenue softness and a less supportive revisions trend into earnings.

8 Analyst Rating

Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74 USD and a high forecast of 99 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

4 Hold

0 Sell

Moderate Buy

Current: 65.020

Low

Averages

88.86

High

Current: 65.020

Low

Averages

88.86

High

Mizuho

Outperform

NULL

downgrade

$90 -> $80

AI Analysis

2026-02-06

New

Reason

Mizuho

Price Target

$90 -> $80

AI Analysis

2026-02-06

New

downgrade

Outperform

NULL

Reason

Mizuho lowered the firm's price target on Haemonetics to $80 from $90 and keeps an Outperform rating on the shares.

Barrington

Outperform

maintain

$93 -> $94

2026-02-06

New

Reason

Barrington

Price Target

$93 -> $94

2026-02-06

New

maintain

Outperform

Reason

Barrington raised the firm's price target on Haemonetics to $94 from $93 and keeps an Outperform rating on the shares following what the firm calls a "mixed bag quarter." Still, Haemonetics updated its FY26 outlook with what the firm calls "solid guidance."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HAE

Unlock Now

HAE Should I Buy

HAE Should I Buy

Should You Buy Haemonetics Corp (HAE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch